Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes
needed for their growth and by blocking blood flow to the tumor.
PURPOSE: This phase II trial is studying how well sunitinib works in treating patients with
progressive metastatic transitional cell cancer of the urothelium.